Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conteltinib + Toripalimab + Gemcitabine in Advanced Pancreatic Cancer
NCT05580445Phase 2Unknown
- Sponsor
- Shouyao Holdings
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of conteltinib in pancreatic cancer (PC), sponsored by Shouyao Holdings. Status: unknown.
02
Drugs
conteltinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05580445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580445.